Skip to main content
TipRanks
Go Ultimate75% OFF

PureTech Health (0VQ0) Q2 2026 Earnings Report

0 Followers

DE:0VQ0 Q2 2026 EPS Results

Actual EPS
EUR 2.46
Consensus EPS
―
Beat/Miss
―
One Year Ago EPS
-EUR 1.69

DE:0VQ0 Q2 2026 Revenue Results

Actual Revenue
EUR 3.16M
Expected Revenue
―
Beat/Miss
―
YoY Revenue Growth
+90.49%

Earnings Announcement Details

Quarter
Q2 2026
Date
09/22/2026
Time
Before Open
Conference Call
Tuesday, September 22, 2026
DE:0VQ0 Upcoming Earnings

PureTech Health's next earnings date is estimated for April 29, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

DE:0VQ0 Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Sep 22, 2026|% Change Since:-2.84%|
Earnings Call Sentiment|Positive

The call was predominantly positive, highlighting successful financing and IPO execution, clinical and regulatory progress, a strong cash runway, lower expected go-forward cash burn and an innovation pipeline ahead of its stated target. The main negatives were the material downgrade in estimated future Cobenfy proceeds, the first-half cash balance decline, higher first-half operating expenses and pending financing requirements for Gallop and Celea.

Company Guidance

Management reiterated operational runway at least through the end of 2028, excluding inflows from potential future monetization events and assuming full deployment of the additional $70 million reserved for potential future investments in Celea; PureTech level cash, cash equivalents and short-term investments were approximately $220 million at June 2026, and go-forward cash burn including overhead and innovation spend is expected to be somewhere between $30 million and $40 million a year versus roughly $90 million a year previously. Gallop intends to complete financing by the first half of next year before initiating the STRIDE-MDS trial, which is expected to enroll approximately 125 patients, with initial projections on the more conservative side indicating probably somewhat under 3 years to complete the study, with actual timing potentially more around 30 months or 33 months; the financing would support Gallop through the readout. PureTech aims to advance at least 3 opportunities to the concept stage each year, expects to share additional detail in the first half of 2027, and estimates approximately $50 million in potential future proceeds from remaining Cobenfy economic rights based on analyst consensus as of mid-August.

  • Progress Against Refined StrategyManagement said PureTech made significant progress in 2026 and meaningfully executed against the refined strategy focused on creating value with greater capital efficiency and translating that value more directly to shareholders.
  • Seaport Therapeutics IPOSeaport Therapeutics completed a successful, oversubscribed IPO on NASDAQ in May. The transcript cites $260 million raised and later specifies $250 million in gross proceeds. PureTech retains a 31.2% equity stake valued at approximately $360 million as of September 18, 2026, along with royalty and milestone rights.
  • Celea Financing and Phase III InitiationCelea Therapeutics secured $180 million from leading healthcare investors and immediately initiated the global Phase III SURPASS-IPF trial for deupirfenidone. PureTech retains a 35.4% equity interest and long-term economics through royalties, milestones and sublicense income rights.
  • Gallop Clinical and Regulatory ProgressGallop Oncology completed its end-of-Phase I meeting with the FDA and received Fast Track designation for LYT-200 in relapsed/refractory high-risk MDS. Gallop is Phase II-ready, PureTech currently owns 100% of the company, and management said the FDA meeting provided clarity on the Phase II STRIDE-MDS trial.
  • Positive LYT-200 Phase Ib FoundationManagement described the Phase Ib results for LYT-200 as positive, citing compelling clinical efficacy and a consistent, favorable safety profile in high-risk MDS patients who had relapsed or become refractory following prior HMA treatment.
  • STRIDE-MDS Trial DesignThe planned randomized, double-blind, placebo-controlled Phase II STRIDE-MDS trial is expected to enroll approximately 125 patients randomized 2:2:1 across LYT-200 at 12 milligrams per kilogram plus an HMA, LYT-200 at 7.5 milligrams per kilogram plus an HMA, or placebo plus an HMA. The study is intended to confirm prior efficacy findings and support dose selection under the FDA's Project Optimus requirements.
  • FDA Support for Mutation-Agnostic ApproachThe FDA accepted Gallop's mutation-agnostic approach and did not require biomarker selection for STRIDE-MDS. Management said the Phase Ib mutation sampling was representative of what may be seen in a subsequent study.
  • Strong Portfolio Economics from CobenfyPureTech said it has generated more than $1 billion from its collective Karuna and Cobenfy economics, while retaining potential Cobenfy-related royalty and milestone payments. The company also highlighted that its portfolio includes three FDA-approved therapeutics, including Cobenfy.
  • Financial Runway Through 2028PureTech ended June 2026 with approximately $220 million in cash, cash equivalents and short-term investments and reiterated that its operational runway extends at least through the end of 2028. The runway excludes inflows from potential future founded-entity monetization events and assumes full deployment of the additional $70 million reserved for potential future investments in Celea.
  • Lower Expected Go-Forward Cash BurnManagement expects go-forward annual cash burn, including overhead and innovation spending, to be between $30 million and $40 million, compared with roughly $90 million per year when later-stage clinical programs were being run internally.
  • Capital-Efficient Hub-and-Spoke ModelPureTech said its hub-and-spoke model allows it to bring in external capital at the founded-entity level while retaining meaningful equity, royalties and milestones. Management said the model has generated evergreen capital through opportunistic monetization without requiring dilutive raises at the PureTech level.
  • LIFE Innovation FrameworkPureTech is applying its LIFE model, or launching innovation from existing pharmacology, by focusing on clinically validated mechanisms and designing solutions to overcome limitations unrelated to efficacy. Management said the approach is intended to support greater speed, lower technical risk and greater capital efficiency.
  • Innovation Pipeline Ahead of TargetPureTech aims to advance at least three opportunities to the concept stage each year, and management said the company is currently running ahead of that target in both the quantity and quality of opportunities. The pipeline includes continued focus on small-molecule therapeutics, CNS opportunities, neuropsychiatry and areas outside CNS.
  • Shareholder-Focused Capital AllocationManagement said it will prioritize maintaining an appropriate operational runway, selectively deploying capital into compelling risk-adjusted opportunities and returning capital to shareholders. The company has reserved $70 million for potential future investment in Celea while retaining flexibility to respond to deal terms and other opportunities.

DE:0VQ0 Earnings History

DE:0VQ0 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Apr 29, 20272026 (Q4)―--2.39――
Sep 22, 20262026 (Q2)―2.46-1.69245.79% (+4.16)
Apr 29, 20262025 (Q4)-1.73-2.393.2-174.69% (-5.60)
Aug 28, 20252025 (Q2)-1.82-1.69-1.33-26.67% (-0.36)
Apr 30, 20252024 (Q4)-2.523.20-1.33340.00% (+4.54)
Aug 28, 20242024 (Q2)-2.70-1.33-0.8-66.67% (-0.53)
Apr 25, 20242023 (Q4)-2.89-1.33-0.69-92.31% (-0.64)
Aug 29, 20232023 (Q2)-0.03-0.80-0.8910.00% (+0.09)
Apr 28, 20232022 (Q4)0.30-0.690.44-256.00% (-1.14)
Aug 25, 20222022 (Q2)-2.44-0.89-2.3161.54% (+1.42)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed